LensGen, Inc.
- Industry
- Medical Devices
- Founded Year
- 2011
- Headquarters
- 15310 Barranca Parkway, Suite 200, Irvine, CA 92618
- Employee Count
- 31
Key People
- Ramgopal Rao - Chief Executive Officer
- Michael Landreville - Chief Operating Officer
- Thomas Silvestrini - Chief Technical Officer
- Daniel Brady - Vice President of Engineering
- Patrick Casey - Vice President of Regulatory Affairs
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team suggests a strong foundation for strategic decision-making and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The Juvene IOL addresses a significant unmet need in treating cataracts and presbyopia.
Cataracts and presbyopia are prevalent conditions affecting millions globally. A solution that effectively restores vision without reliance on spectacles addresses a substantial clinical need.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing solutions, but Juvene offers unique advantages.
The intraocular lens market includes established players; however, Juvene's fluid-optic technology provides a novel solution that could capture market share.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a fluid-optic IOL presents manageable technical challenges.
Implementing fluid-optic technology in an intraocular lens involves complexities in design and biocompatibility, but these challenges are within the realm of current engineering capabilities.
- Patent
-
Aspect: Very Strong
Summary: LensGen holds comprehensive patents protecting its technology.
The granting of broad patents by the US Patent Office secures LensGen's proprietary technology, providing a significant barrier to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors.
With over $90 million raised from investors like HOYA Group and Relativity Healthcare Partners, LensGen is well-positioned financially to advance its product through clinical trials and market entry.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Juvene is progressing through pivotal clinical trials.
The company's advancement into pivotal trials indicates significant progress, but regulatory approval is contingent upon demonstrating safety and efficacy in these studies.
Opportunity Rollup
- Odds of Success
- 3.85
- Peak Market Share
- 4.85
- Segment CAGR
- 3.2%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- Intraocular Lenses
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.39 |
| 5 | 4.85 |
Key Takeaway
LensGen's Juvene IOL addresses a significant clinical need with innovative technology, supported by strong leadership and financial backing, positioning it well in a competitive market.